SLCs are emerging as promising targets for the treatment of cancer (SLC7A4 (refs. 54,55), SLC1A5 (refs. 56,57) and SLC7A5 (ref. 58)) and other diseases such as diabetes (SLC5A1/SLC5A2 (ref. 59)). This evidence concerns the gene SLC1A5 and diabetes mellitus.